Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Integrating pharmacokinetics and pharmacodynamics in operational research to End TB.

Alffenaar JC, Gumbo T, Dooley KE, Peloquin CA, McIlleron H, Zagorski A, Cirillo DM, Heysell SK, Silva DR, Migliori GB.

Clin Infect Dis. 2019 Sep 27. pii: ciz942. doi: 10.1093/cid/ciz942. [Epub ahead of print]

PMID:
31560376
2.

The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.

Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Review.

PMID:
31486393
3.

Erratum for DeMarco et al., "Determination of [11C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging".

DeMarco VP, Ordonez AA, Klunk M, Prideaux B, Wang H, Zhang Z, Tonge PJ, Dannals RF, Holt DP, Lee CKK, Weinstein EA, Dartois V, Dooley KE, Jain SK.

Antimicrob Agents Chemother. 2019 Aug 23;63(9). pii: e01368-19. doi: 10.1128/AAC.01368-19. Print 2019 Sep. No abstract available.

4.

Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.

Tucker EW, Pieterse L, Zimmerman MD, Udwadia ZF, Peloquin CA, Gler MT, Ganatra S, Tornheim JA, Chawla P, Caoili JC, Ritchie B, Jain SK, Dartois V, Dooley KE.

Antimicrob Agents Chemother. 2019 Sep 23;63(10). pii: e00913-19. doi: 10.1128/AAC.00913-19. Print 2019 Oct.

PMID:
31383662
5.

Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosis.

Sekaggya-Wiltshire C, Dooley KE.

Expert Opin Drug Metab Toxicol. 2019 Aug;15(8):615-618. doi: 10.1080/17425255.2019.1648432. Epub 2019 Jul 30. No abstract available.

PMID:
31339806
6.

Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.

Radtke KK, Dooley KE, Dodd PJ, Garcia-Prats AJ, McKenna L, Hesseling AC, Savic RM.

Lancet Child Adolesc Health. 2019 Sep;3(9):636-645. doi: 10.1016/S2352-4642(19)30196-8. Epub 2019 Jul 16.

PMID:
31324596
7.

Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.

Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM.

PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul. No abstract available.

8.

Sub-therapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes.

Ramachandran G, Chandrasekaran P, Gaikwad S, Hemanth Kumar AK, Thiruvengadam K, Gupte N, Paradkar M, Dhanasekaran K, Sivaramakrishnan GN, Kagal A, Thomas B, Pradhan N, Kadam D, Hanna LE, Balasubramanian U, Kulkarni V, Murali L, Golub J, Gupte A, Shivakumar SVBY, Swaminathan S, Dooley KE, Gupta A, Mave V; C-TRIUMPh team.

Clin Infect Dis. 2019 May 10. pii: ciz380. doi: 10.1093/cid/ciz380. [Epub ahead of print]

PMID:
31075166
9.

Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.

Hong H, Dooley KE, Starbird LE, Francis HW, Farley JE.

Arch Toxicol. 2019 May;93(5):1385-1399. doi: 10.1007/s00204-019-02407-8. Epub 2019 Apr 8.

PMID:
30963202
10.

Aminoglycoside-Induced Hearing Loss Among Patients Being Treated for Drug-Resistant Tuberculosis in South Africa: A Prediction Model.

Hong H, Dowdy DW, Dooley KE, Francis HW, Budhathoki C, Han HR, Farley JE.

Clin Infect Dis. 2019 Apr 9. pii: ciz289. doi: 10.1093/cid/ciz289. [Epub ahead of print]

PMID:
30963176
11.

Pharmacologic Research in Pregnant Women - Time to Get It Right.

Eke AC, Dooley KE, Sheffield JS.

N Engl J Med. 2019 Apr 4;380(14):1293-1295. doi: 10.1056/NEJMp1815325. No abstract available. Erratum in: N Engl J Med. 2019 Jul 11;381(2):194.

PMID:
30943333
12.

Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial.

Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait-Khaled M, Angelis K, Brown D, Singh R, Talarico CL, Tenorio AR, Keegan MR, Aboud M; INSPIRING study group.

Clin Infect Dis. 2019 Mar 28. pii: ciz256. doi: 10.1093/cid/ciz256. [Epub ahead of print]

PMID:
30918967
13.

Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.

O'Donnell MR, Padayatchi N, Daftary A, Orrell C, Dooley KE, Rivet Amico K, Friedland G.

Lancet HIV. 2019 Mar;6(3):e201-e204. doi: 10.1016/S2352-3018(19)30035-9.

PMID:
30846058
14.

Intensified antibiotic treatment of tuberculosis meningitis.

Cresswell FV, Te Brake L, Atherton R, Ruslami R, Dooley KE, Aarnoutse R, Van Crevel R.

Expert Rev Clin Pharmacol. 2019 Mar;12(3):267-288. doi: 10.1080/17512433.2019.1552831. Epub 2019 Feb 12. Review.

PMID:
30474434
15.

The Global Landscape of Tuberculosis Therapeutics.

Tornheim JA, Dooley KE.

Annu Rev Med. 2019 Jan 27;70:105-120. doi: 10.1146/annurev-med-040717-051150. Epub 2018 Nov 7.

PMID:
30403551
16.

State-of-the-Art Review of HIV-TB Coinfection in Special Populations.

Weld ED, Dooley KE.

Clin Pharmacol Ther. 2018 Dec;104(6):1098-1109. doi: 10.1002/cpt.1221. Epub 2018 Oct 26. Review.

PMID:
30137652
17.

Effect of Diabetes Mellitus on the Pharmacokinetics and Pharmacodynamics of Tuberculosis Treatment.

Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, Gupte N, Kulkarni V, Deshmukh S, Atre S, Raskar S, Lokhande R, Barthwal M, Kakrani A, Chon S, Gupta A, Golub JE, Dooley KE.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01383-18. doi: 10.1128/AAC.01383-18. Print 2018 Nov.

18.

Challenges of TB and HIV co-treatment: updates and insights.

Tornheim JA, Dooley KE.

Curr Opin HIV AIDS. 2018 Nov;13(6):486-491. doi: 10.1097/COH.0000000000000495. Review.

PMID:
30080683
19.

High-Dose Rifampin: Shall We Be Bolder?

Dooley KE.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):558-560. doi: 10.1164/rccm.201806-1140ED. No abstract available.

PMID:
29993257
20.

Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?

Dooley KE.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):833-834. doi: 10.5588/ijtld.18.0411. No abstract available.

PMID:
29991389
21.

The Global Neurological Burden of Tuberculosis.

Thakur K, Das M, Dooley KE, Gupta A.

Semin Neurol. 2018 Apr;38(2):226-237. doi: 10.1055/s-0038-1651500. Epub 2018 May 23. Review.

PMID:
29791949
22.

Preclinical tools for the evaluation of tuberculosis treatment regimens for children.

Tucker EW, Dooley KE.

Int J Tuberc Lung Dis. 2018 May 1;22(5):7-14. doi: 10.5588/ijtld.17.0354. Review.

PMID:
29665948
23.

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. doi: 10.1126/scitranslmed.aai7786.

24.

The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs.

Sekaggya-Wiltshire C, Lamorde M, Kiragga AN, Dooley KE, Kamya MR, Kambugu A, Fehr J, Manabe YC, Castelnuovo B.

Tuberculosis (Edinb). 2018 Jan;108:77-82. doi: 10.1016/j.tube.2017.11.004. Epub 2017 Nov 7. Review.

25.

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM.

Clin Pharmacokinet. 2018 Nov;57(11):1421-1433. doi: 10.1007/s40262-018-0642-9.

26.

HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression.

Warburton A, Redmond CJ, Dooley KE, Fu H, Gillison ML, Akagi K, Symer DE, Aladjem MI, McBride AA.

PLoS Genet. 2018 Jan 24;14(1):e1007179. doi: 10.1371/journal.pgen.1007179. eCollection 2018 Jan.

27.

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM.

Clin Pharmacol Ther. 2018 Oct;104(4):733-741. doi: 10.1002/cpt.987. Epub 2018 Feb 2.

28.

Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.

Mave V, Kinikar A, Kagal A, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Gerona R, Wen A, Ramachandran G, Kumar H, Bacchetti P, Dooley KE, Gupte N, Gupta A, Gandhi M.

PLoS One. 2017 Dec 7;12(12):e0189101. doi: 10.1371/journal.pone.0189101. eCollection 2017.

29.

Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.

Denti P, Garcia-Prats AJ, Draper HR, Wiesner L, Winckler J, Thee S, Dooley KE, Savic RM, McIlleron HM, Schaaf HS, Hesseling AC.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01521-17. doi: 10.1128/AAC.01521-17. Print 2018 Feb.

30.

Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa: The Tshepiso Study.

Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S, Hoffmann C, Dooley KE, Chaisson RE, Martinson N; TSHEPISO Study Team.

Clin Infect Dis. 2018 Mar 5;66(6):921-929. doi: 10.1093/cid/cix851.

31.

Tuberculous meningitis.

Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, Caws M, Figaji A, Savic R, Solomons R, Thwaites GE; Tuberculous Meningitis International Research Consortium.

Nat Rev Neurol. 2017 Oct;13(10):581-598. doi: 10.1038/nrneurol.2017.120. Epub 2017 Sep 8. Review.

PMID:
28884751
32.

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, Peloquin CA.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review.

PMID:
28803492
33.

In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis.

Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G.

J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152.

34.

New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM.

Clin Transl Sci. 2017 Sep;10(5):366-379. doi: 10.1111/cts.12472. Epub 2017 May 31.

35.

Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.

McIlleron H, Denti P, Cohn S, Mashabela F, Hoffmann JD, Shembe S, Msandiwa R, Wiesner L, Velaphi S, Lala SG, Chaisson RE, Martinson N, Dooley KE; Tshepiso Study Team.

J Antimicrob Chemother. 2017 Jul 1;72(7):2028-2034. doi: 10.1093/jac/dkx112.

36.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
37.

The time has come: sparing injectables in paediatric MDR-TB.

Weld ED, Garcia-Prats AJ, Furin JJ, Bailey TC, Hesseling AC, Dooley KE.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30078-4. doi: 10.1016/S2213-2600(17)30078-4. [Epub ahead of print] No abstract available.

PMID:
28344008
38.

Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.

Alsultan A, Savic R, Dooley KE, Weiner M, Whitworth W, Mac Kenzie WR, Peloquin CA; Tuberculosis Trials Consortium.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02625-16. doi: 10.1128/AAC.02625-16. Print 2017 Jun.

39.

Tuberculosis Associated with HIV Infection.

Tornheim JA, Dooley KE.

Microbiol Spectr. 2017 Jan;5(1). doi: 10.1128/microbiolspec.TNMI7-0028-2016. Review.

PMID:
28233512
40.

Importance of Drug Pharmacokinetics at the Site of Action.

Rizk ML, Zou L, Savic RM, Dooley KE.

Clin Transl Sci. 2017 May;10(3):133-142. doi: 10.1111/cts.12448. Epub 2017 Feb 3. Review. No abstract available.

41.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

42.

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW.

PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.

43.

Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities.

McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR.

Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. Review.

44.

Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes.

Dooley KE, Warburton A, McBride AA.

MBio. 2016 Sep 13;7(5). pii: e01446-16. doi: 10.1128/mBio.01446-16.

45.

A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.

Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.

PLoS One. 2016 May 9;11(5):e0154778. doi: 10.1371/journal.pone.0154778. eCollection 2016.

46.

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.

Mave V, Chandanwale A, Kinikar A, Khadse S, Kagal A, Gupte N, Suryavanshi N, Nimkar S, Koli H, Khwaja S, Bharadwaj R, Joshi S, Horng H, Benet LZ, Ramachandran G, Dooley KE, Gupta A, Gandhi M.

Int J Tuberc Lung Dis. 2016 Jun;20(6):844-7. doi: 10.5588/ijtld.15.0882.

47.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

48.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

49.

Challenges in the clinical assessment of novel tuberculosis drugs.

Dooley KE, Phillips PP, Nahid P, Hoelscher M.

Adv Drug Deliv Rev. 2016 Jul 1;102:116-22. doi: 10.1016/j.addr.2016.01.014. Epub 2016 Jan 28. Review.

50.

Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel.

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A.

Clin Infect Dis. 2016 Mar 15;62(6):761-769. doi: 10.1093/cid/civ991. Epub 2015 Dec 9.

Supplemental Content

Loading ...
Support Center